CAS No. : 51543-40-9

Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I003858
Synonyms:(2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid
Molecular Formula:C15H13FO2
Molecular Weight:244.3
Target:Gamma Secretase
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

Appearance:Solid powder
Purity: > 98%
Cat No:I003858
Cas No:51543-40-9

(R)-Flurbiprofen is the R-enantiomer of the racemate NSAID Flurbiprofen, (R)-Flurbiprofen inhibits the binding of [3H]9-cis-RA to RXRα LBD with IC50 of 75 μM.
IC50 & Target: 75 μM (RXRα)[1]
InVitro: (R)-Flurbiprofen can significantly reduce Aβ secretion, but at the same time, increases the level of intracellular Aβ. The binding between [3H]9-cis-RA and RXRα is competitively inhibited by both unlabeled (R)-Flurbiprofen and 9-cis-RA. (R)-Flurbiprofen can interfere with the interaction between RXRα and 9-cis-retinoid acid (9-cis-RA), and that 9-cis-RA decreases (R)-Flurbiprofen’s reduction of Aβ secretion. (R)-Flurbiprofen treatment significantly increases the levels of intracellular Aβ species[1]. The well characterized, nonsteroidal anti-inflammatory drug (nonsteroidal anti-inflammatory drug), R-Flurbiprofen affects only Aβ and not Notch β formation, indicating that second generation GSMs and nonsteroidal anti-inflammatory drug-based GSMs have different modes of action regarding Notch processing[2].
InVivo: Effects of the early and late onset of treatment with R-Flurbiprofen are assessed in C57BL6/J mice that develop a non-remitting form of the disease, and in SJL mice that develop a relapsing-remitting (RR)-EAE. R-Flurbiprofen completely prevents the development of clinical EAE scores in C57BL6/J mice when the treatment is started within 3 days after immunization. This regimen is referred to as preventive treatment. The effect is dose-dependent, and the minimum daily dose for complete prevention is 5 mg/kg/day. Effects of R-Flurbiprofen are comparable to those of Fingolimod (FTY720, 0.5 mg/kg/day), which is used as the positive control. R-Flurbiprofen also significantly reduces clinical EAE scores in C57BL6/J mice when treatment is started shortly before onset of clinical manifestations, referred to as semi-therapeutic (10 mg/kg/day) and reduces clinical scores when the treatment is initiated after full development of the disease on day 13 (5 mg/g/day)[3].

1:A pH-independent instantaneous release of flurbiprofen: a study of the preparation of complexes, their characterization and in vitro/in vivo evaluation. Wang HB, Yang FF, Gai XM, Cheng BC, Li JY, Pan H, Yang XG, Pan WS.Drug Dev Ind Pharm. 2017 Apr 24:1-12. doi: 10.1080/03639045.2017.1318908. [Epub ahead of print] PMID: 28402143
2:Ultrafast Fluorescence Dynamics in Flurbiprofen-Amino Acid Dyads and in the Supramolecular Drug/Protein Complex. Vayá I, Jiménez MC, Miranda MA, Chatterjee A, Gustavsson T.Chimia (Aarau). 2017 Feb 22;71(1):18-25. doi: 10.2533/chimia.2017.18. PMID: 28259191
3:Enantioselective Effect of Flurbiprofen on Lithium Disposition in Rats. Uwai Y, Matsumoto M, Kawasaki T, Nabekura T.Pharmacology. 2017;99(5-6):236-239. doi: 10.1159/000455917. Epub 2017 Feb 2. PMID: 28147361
4:Preoperative butorphanol and flurbiprofen axetil therapy attenuates remifentanil-induced hyperalgesia after laparoscopic gynaecological surgery: a randomized double-blind controlled trial. Zhang L, Shu R, Zhao Q, Li Y, Yu Y, Wang G.Br J Anaesth. 2016 Oct;117(4):504-511. doi: 10.1093/bja/aew248. Epub 2016 Oct 17. PMID: 28077539
5:R-Flurbiprofen Traps Prostaglandins within Cells by Inhibition of Multidrug Resistance-Associated Protein-4. Wobst I, Ebert L, Birod K, Wegner MS, Hoffmann M, Thomas D, Angioni C, Parnham MJ, Steinhilber D, Tegeder I, Geisslinger G, Grösch S.Int J Mol Sci. 2016 Dec 30;18(1). pii: E68. doi: 10.3390/ijms18010068. PMID: 28042832 Free PMC Article
6:Novel flurbiprofen derivatives with improved brain delivery: synthesis, in vitro and in vivo evaluations. Zheng D, Shuai X, Li Y, Zhou P, Gong T, Sun X, Zhang Z.Drug Deliv. 2016 Sep;23(7):2183-2192. Epub 2014 Sep 3. PMID: 25182481
7:Protective effects of dexmedetomidine combined with flurbiprofen axetil on remifentanil-induced hyperalgesia: A randomized controlled trial. Yu Z, Wu W, Wu X, Lei H, Gong C, Xu S.Exp Ther Med. 2016 Oct;12(4):2622-2628. Epub 2016 Sep 8. PMID: 27698764 Free PMC Article
8:Preoperative But Not Postoperative Flurbiprofen Axetil Alleviates Remifentanil-induced Hyperalgesia After Laparoscopic Gynecological Surgery: A Prospective, Randomized, Double-blinded, Trial. Zhang L, Shu R, Zhao Q, Li Y, Wang C, Wang H, Yu Y, Wang G.Clin J Pain. 2017 May;33(5):435-442. doi: 10.1097/AJP.0000000000000416. PMID: 27518488
9:Aging Enables Ca2+ Overload and Apoptosis Induced by Amyloid-β Oligomers in Rat Hippocampal Neurons: Neuroprotection by Non-Steroidal Anti-Inflammatory Drugs and R-Flurbiprofen in Aging Neurons. Calvo-Rodríguez M, García-Durillo M, Villalobos C, Núñez L.J Alzheimers Dis. 2016 Jul 22;54(1):207-21. doi: 10.3233/JAD-151189. PMID: 27447424
10:Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration. Song A, Zhang X, Li Y, Mao X, Han F.Drug Dev Ind Pharm. 2016 Aug;42(8):1308-14. doi: 10.3109/03639045.2015.1132226. Epub 2016 Jan 20. PMID: 26707734
Related Products
  • CAS No. :1194044-20-6
    Product Name:


    Cat No: I000703 View details
  • CAS No. :173550-33-9
    Product Name:

    Compound W

    Cat No: M044843 View details
  • CAS No. :1146699-66-2
    Product Name:


    Cat No: I000544 View details
  • CAS No. :677772-84-8
    Product Name:


    Cat No: I008017 View details